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West Nile (WN) virus (1) outbreaks were recorded in
Israel during the 1950s and 1970s (2-4); however, in the last
decade, diagnosis ceased and no clinical cases were reported,
although seroepidemiologic surveys indicated that the virus
continued to circulate (5). Following reports of illness in birds
in 1998, the Central Virology Laboratory (CVL) of the Public
Health Services reestablished the capability to diagnose WN
virus based on serologic assays, including virus neutraliza-
tion, immunofluorescence, and enzyme-linked immunosor-
bent assays (ELISA) with immunoglobulin (Ig) G and IgM.
This led to the identification of acute human cases
beginning in the fall of 1999 (6). High seroprevalence was
found in the southern region of Israel (Eilot region) in the fall
and winter of 1999-2000, with IgG levels ranging from 21% to
82% and IgM levels ranging from 0% to 73% in seven
communities. Some IgM-positive cases were associated with
clinical symptoms compatible with WN fever. Additional
acute cases were diagnosed in the central region of Israel
during the spring and summer of 2000 (H. Bin, unpub. data).
During the late summer and fall of 2000, an outbreak
occurred in the central and northern parts of Israel. Between
August 1 and November 30, 439 patients with clinical
symptoms were positive by ELISA-IgM testing; 29 of these
patients died. The clinical details in records of the patients
diagnosed at the CVL indicated that central nervous system
(CNS) involvement was a major clinical manifestation in most
hospitalized patients. Rates of illness and death increased with
age: 69% of the patients were >45 years and 96% of those who
died were >65 (Quarterly Report No. 3 of the Department of
Epidemiology, Ministry of Health, Jerusalem). Epidemiologic
and clinical aspects of the outbreak were also described by
Weinberger et al. (7) and Chowers et al. (8), respectively. We
describe the isolation and characterization of four viral strains
from human serum obtained during this outbreak.
The Study
During the outbreak, patients’ samples (serum,
cerebrospinal fluid [CSF], or both) submitted to the CVL were
immediately divided into two aliquots. One aliquot was
immediately used to test for IgM antibodies, and the other
was stored at -70°C until further processing. Virologic studies
were performed on the frozen acute-phase samples from
patients who seroconverted from IgM negative to IgM
positive, as well as on CSF from fatal cases. Reverse
transcription-polymerase chain reaction (RT-PCR) and virus
isolation were attempted simultaneously on 32 patients’
samples (17 serum and 15 CSF). RT-PCR and an indirect
immunofluorescence assay (IFA) were used to confirm the
presence of WN virus in cell culture. Direct sequencing of RT-
PCR amplified fragments was performed to characterize the
genome of isolated viruses.
Patient samples were analyzed for WN virus by RT-PCR
using primer sequences for the envelope gene, as described by
Lanciotti et al. and Shi et al. (9,10). Viral RNA was extracted
by using the QIAamp Viral RNA Mini Kits (QIAgen Gmbh,
Hilden, Germany), and the RT-PCR was performed with
Ready to Go Beads (Amersham Pharmacia, Buckingham-
shire, England) according to manufacturer’s instructions. The
primers Kun 108, Kun 848, Kun 998c, and Kun 1830c were
used in RT-PCR for sequence analysis (11). Sequence analysis
was performed on a 1648-bp fragment of the WN virus genome
encoding 309 nt upstream from the pre-membrane protein
(preM), the entire preM and membrane protein (M) genes, and
811 nt of the 5' portion of the envelope glycoprotein (E) gene.
Purification of the RT-PCR product and sequence and
phylogenetic analyses were performed as described (12). Both
strands of the amplified PCR products were sequenced. RT-
PCR conditions used were 42°C for 45 min, 95°C for 5 min,
60°C for 2 min, 72°C for 2 min, 34 cycles at 93°C for 45 sec,
55°C for 45 sec, and 72°C for 90 sec, followed by 72°C for 7 min;
samples were then left at 4°C. PCR products were visualized
by staining with ethidium bromide after electrophoresis on
2% agarose gels. With the RT-PCR assay, we can detect as low
as 0.01 PFU based on serially diluted titered WN virus
isolated from a White-eyed Gull.
Virus isolation was performed on Vero cell monolayers
(ATCC CCL-81) by using the tube method. Vero cell
monolayers (80%-90% confluent) were washed twice with
phosphate-buffered saline, then infected with 100- to 200-µL
patient samples. Patient samples were allowed to adsorb for 1
hour at 37°C with gentle swirling every 15 min. Eagle’s
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minimal essential medium with 2% fetal calf serum, 100 U/
mL penicillin, 200 µg/mL streptomycin, and 12.5 U/mL
nystatin was then added to the infected cells. Cells were
monitored daily for 7 days for cytopathic effect (CPE). Cells
showing CPE demonstrated rounding-up in the early stage of
infection and many floating single cells later in the infection.
Infected cells that showed CPE were evaluated by RT-PCR,
and a sample (100 µL) of the supernatant was passaged on
another Vero cell monolayer to confirm WN virus. Infected
cells that showed CPE were also evaluated by IFA using the
monoclonal antibody JCU/KUN/2B2 (TropBio Pty Ltd.,
Townsville Queensland, Australia) (13). Cells from monolay-
ers that did not show CPE were passaged onto fresh Vero cell
monolayers and monitored for another 7 days. Cells that did
not show CPE after 14 days were also tested with the IFA
reagent. Only cell cultures that did not stain with IFA were
reported negative.
Virus was isolated from serum from four nonfatal WN
virus IgM-negative Israeli patients who seroconverted 1 to 2
weeks later. Patient 1 (WN-0043), a 51-year-old woman from
the northcentral region, was hospitalized; CNS disease did
not develop. Patient 2 (WN-0233), a 20-year-old man from the
north, was hospitalized for fever of unknown origin and
neutropenia; CNS disease did not develop. Patient 3 (WN-
0247), a 5-year-old boy residing in the central region, had
meningoencephalitis and was hospitalized. Patient 4 (WN-
0304), a 55-year-old woman from the north, had high fever
and myalgia and no CNS symptoms; she was not hospitalized.
Two viral isolates were detected from patients 3 and 4 on
day 4 after inoculation on Vero cells; the other two isolates
were detected from patients 1 and 2 on day 7 after inoculation.
All four virus isolates were confirmed as WN virus by IFA.
Only two original acute-phase serum samples (patients 3 and
4) were positive by RT-PCR. Negative RT-PCR results and
lengthy time until appearance of CPE are apparently
consistent with low viral load in patients’ serum (Table).
Sequence analysis showed that isolates WN-0233
(GenBank Accession Number AF375043) and WN-0304
(GenBank Accession Number AF375045) had identical
sequences over 1,648 nt and isolates WN-0043 (GenBank
Accession Number AF375042) and WN-0247 (GenBank
Accession Number AF375044) differed by only 1 nt. Such high
homology is similar to results reported by Lanciotti et al., who
also described identical WN virus sequences from brain
samples from two patients (14). WN-0247 differed from WN-
0304 by 50 (3%) of 1,648 nts or 25 (2.9%) of 855 nt for the
partial E gene sequence. Most differences in the E gene were
in the third position of the codon (21 of 25); all of these were
synonymous. All four differences in the first and second codon
positions encoded different amino acids when isolate WN-
0247 was compared with isolate WN-0304.
A 255-nt fragment of the WN virus E gene has previously
been used for phylogenetic studies (15-17). A search of the
EMBL/GenBank database using the equivalent fragment of
the Israeli outbreak isolates indicated that isolate WN-0043
and WN-0247 were identical to WN-flamingo-NY99, while
isolates WN-0233 and WN-0304 were most closely related to
the WN-Romania-97 isolate AF130362 (3-nt difference, 1.2%)
and less closely related to the WN-flamingo-Y99 (9-nt
difference, 3.5%).
A similar search, using a 1,648-nt fragment encoding the
preM, M, and part of the 5' E gene, allowed the construction of
a more detailed phylogenetic comparison (Figure). As with the
255-nt fragment, WN-0043 and WN-0247 were closest to WN-
flamingo-NY99 (AF196835, 99.7% homology), while WN-
0233 and WN-0304 most closely resembled a 1997 isolate
from Romania (AF130362, 98.4% homology). Phylogenetic
analysis showed that two lineages of WN virus circulate in
Israel. The first is similar to the WN virus isolates from
mosquito, horse, and flamingo during the 1999 NY outbreak.
The other lineage is similar to the virus isolated from a
mosquito pool during the 1997 Romanian outbreak and to the
nucleotide sequences reported from the Russian outbreak in
Figure. Phylogenetic comparison of human West Nile virus isolates
from the Israel 2000 outbreak with sequences from the EMBL/
GenBank database. The PHYLIP DNA Maximum Likelihood
program (bootstrap = 100) was used to compare a 1,648-nt sequence
encoding the PreM, M gene, and part of the E gene from the four
human outbreak isolates with nine sequences from the EMBL/
GenBank database (accession numbers in parentheses) and one from
a 1999 isolate from an Israeli White-eyed Gull. CSF = cerebrospinal
fluid sample.
Table. Analysis of West Nile patients’ isolates, Israel, 2000 outbreak
   Tissue    RT-PCR
   culture    & tissue
RT-PCR     acute- RT-PCR     culture
  acute-     phase infected convalescent-
  Virus   phase     serum    cell      phase
Patients   isolate   serum (CPE+IFA) culture      serum
1 WN-0043 (-) (+) (+) ND
2 WN-0233 (-) (+) (+) ND
3 WN-0247 (+) (+) (+)  (-)
4 WN-0304 (+) (+) (+)  (-)
+, positive result; -, negative result; ND, not done; RT-PCR, reverse
transcription-polymerase chain reaction; CPE, cytopathic effect; IFA, indirect
immunofluorescence assay.750 Emerging Infectious Diseases Vol. 7, No. 4, July–August 2001
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1999. These two lineages isolated in Israel in the 2000
outbreak differ from the WN sequences obtained in 1996 from
Romania (11).
Conclusions
Our sequence analysis shows that at least two lineages of
WN virus infected the human population in Israel in 2000.
Virus lineage and severity of symptoms were not clearly
correlated, although more human isolates would be necessary
to confirm this finding. More than one lineage can be found in
areas where a virus is endemic and has been circulating for
extended periods. More studies, using archived materials, are
necessary to determine if there were more than two co-
circulating lineages. Yet to be determined is whether changes
in the virus genome resulted in a more virulent strain, which
caused the high rates of illness and death during the 2000
Israeli outbreak.
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